Re: late cost transfers Gadi, Juan Felix M 17 Jan 2007 13:40 EST
I can tell you of a war story of an 18-month delayed charge and award on an ongoing capitated clinical study of a center grant. Bottom line was I had to prove that these were legitimate charges to the funding agency who in turn issued a revised NGA. In other words, work with the funding agency and get their approval. With that, all else will fall in place. As for the monies, the center grant was capitated clinical multi-studies and we were allowed to use the monies for the other studies of the center grant. I hope this helps. J. Felix Gadi C&G Specialist Integrative Biology & Pharmacology The University of Texas Health Science Center at Houston ________________________________ From: Research Administration List on behalf of Linda Ward Sent: Wed 1/17/2007 11:33 AM To: xxxxxx@hrinet.org Subject: [RESADM-L] late cost transfers We are working on processes for cost transfers, and are seeking your advice on whether there are exceptions to the 90 day rule: * Are there justifiable execptions to the 90 day policy? * If there are justifiable exceptions, who do you have approve them? * What do you do when a late (over 90 days) cost transfer reduces the federal obligation (expense) on an award? * What do you do when a late cost transfer relates only to non federal awards - are you more lenient? * What do you do when a late cost transfer, if not processed, effectively increases the PI residual on a fixed fee (for example, a clinical trial) award? You input is greatly appreciated!! Linda Ward Grant Accounting Supervisor Research Administration 35-123A Children's Hospitals and Clinics of Minnesota 2910 Centre Pointe Dr. Roseville, MN 55113 651-855-2603 651-855-2690 Fax email: xxxxxx@childrensmn.org _______________________________________________________________ Confidentiality Statement: This email/fax, including attachments, may include confidential and/or proprietary information and may be used only by the person or entity to which it is addressed. If the reader of this email/fax is not the intended recipient or his or her agent, the reader is hereby notified that any dissemination, distribution or copying of this email/fax is prohibited. If you have received this email/fax in error, please notify the sender by replying to this message and deleting this email or destroying this facsimile immediately. ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ====================================================================== ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ======================================================================